ADMA Biologics Company Profile (NASDAQ:ADMA)

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics logoADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMA
  • CUSIP: N/A
  • Web:
  • Market Cap: $52.32 million
  • Outstanding Shares: 12,886,000
Average Prices:
  • 50 Day Moving Avg: $3.79
  • 200 Day Moving Avg: $4.62
  • 52 Week Range: $2.93 - $8.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.17 million
  • Price / Sales: 4.68
  • Book Value: ($0.83) per share
  • Price / Book: -4.89
  • EBIDTA: ($18,640,000.00)
  • Net Margins: -191.99%
  • Return on Equity: -6,405.90%
  • Return on Assets: -85.33%
  • Debt-to-Equity Ratio: -1.01%
  • Current Ratio: 1.21%
  • Quick Ratio: 0.80%
  • Average Volume: 32,916 shs.
  • Beta: 2.56
  • Short Ratio: 2.26

Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings results on Friday, May, 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to analyst estimates of $3.35 million. ADMA Biologics had a negative net margin of 191.99% and a negative return on equity of 6,405.90%. View ADMA Biologics' Earnings History.

When will ADMA Biologics make its next earnings announcement?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Thursday, August, 10th 2017. View Earnings Estimates for ADMA Biologics.

Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?

2 brokers have issued 1-year price objectives for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' share price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:

  • Steven A. Elms, Chairman of the Board
  • Adam S. Grossman, President, Chief Executive Officer, Director
  • Jerrold B. Grossman D.P.S, Vice Chairman of the Board
  • Brian Lenz, Chief Financial Officer
  • James Mond M.D., Ph.D., Chief Scientific and Medical Officer
  • Bernhard R. M. Ehmer, Director
  • Bryant E. Fong, Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Lawrence P. Guiheen, Independent Director
  • Eric I. Richman, Independent Director

Who owns ADMA Biologics stock?

ADMA Biologics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BIOTEST AG (25.00%), Aisling Capital LLC (0.00%), Biomark Capital Management Co. LLC (0.00%), Broadfin Capital LLC (7.98%), Perceptive Advisors LLC (5.60%) and FMR LLC (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.

Who sold ADMA Biologics stock? Who is selling ADMA Biologics stock?

ADMA Biologics' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Weiss Multi Strategy Advisers LLC and FMR LLC. View Insider Buying and Selling for ADMA Biologics.

Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?

ADMA Biologics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.

How do I buy ADMA Biologics stock?

Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA Biologics stock can currently be purchased for approximately $4.06.

MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.00 (220.20% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/7/2017Maxim GroupSet Price TargetBuy$13.00LowView Rating Details
8/1/2016Raymond James Financial, Inc.DowngradeStrong-Buy -> Market PerformN/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for ADMA Biologics (NASDAQ:ADMA)
Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)
Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.28)($0.51)$3.35 million$2.63 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.42)($0.34)$2.32 million$2.94 millionViewN/AView Earnings Details
8/12/2016Q2($0.39)($0.50)$2.35 million$2.27 millionViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)$2.48 million$2.12 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.32)($0.37)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.32)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.38)($0.38)$1.52 million$1.41 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.37)($0.36)$1.37 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)


Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 71.65%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
DateHeadline logoADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders - June 27 at 3:24 PM logoBRIEF-Adma Biologics says approved 5 pct increases in annual cash bonuses to CEO, CFO among others - June 9 at 8:26 PM logoADMA Biologics (ADMA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 8:26 PM logoZacks: ADMA Biologics Inc (ADMA) Given $10.50 Average Target Price by Brokerages - June 8 at 8:50 AM logoADMA Biologics Inc (ADMA) Given a $13.00 Price Target by Maxim Group Analysts - June 7 at 7:18 PM logoBRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc. - June 7 at 3:24 PM logoADMA Biologics Completes Acquisition of Biotest’s Therapy Business Unit Assets - June 6 at 8:33 PM logoETFs with exposure to ADMA Biologics, Inc. : June 5, 2017 - June 5 at 6:41 PM logoZacks: Brokerages Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $3.32 Million - June 4 at 7:54 AM logoADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.30 Per Share - June 2 at 6:24 PM logoADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 - June 2 at 4:15 PM logoADMA Biologics to Present at Jefferies 2017 Healthcare Conference - May 25 at 8:38 PM logoADMA: 1Q:17 Results and Biotest Acquisition: Valuation Implications - May 19 at 8:19 PM logoADMA Biologics Inc to Post Q2 2017 Earnings of ($0.30) Per Share, Zacks Investment Research Forecasts (ADMA) - May 18 at 8:42 AM logoADMA Biologics Inc (ADMA) Announces Earnings Results - May 15 at 10:58 AM logoBRIEF-ADMA Biologics Q1 loss per share $0.51 - May 13 at 3:23 PM logoADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results - May 12 at 8:54 PM logoAdma Biologics reports 1Q loss - May 12 at 8:54 PM logoADMA Biologics Inc (ADMA) to Release Quarterly Earnings on Thursday - May 9 at 7:00 AM logoADMA Biologics (ADMA) Receiving Positive News Coverage, Report Finds - May 4 at 7:54 AM logoADMA Biologics (ADMA) Earns Daily News Sentiment Rating of 0.37 - April 26 at 2:08 PM logoADMA Biologics (ADMA) Receiving Very Positive Press Coverage, AlphaOne Reports - April 23 at 7:38 AM logoETFs with exposure to ADMA Biologics, Inc. : April 20, 2017 - April 20 at 3:21 PM logoADMA Biologics (ADMA) Receives Coverage Optimism Rating of 0.33 - April 15 at 8:46 AM logoETFs with exposure to ADMA Biologics, Inc. : April 7, 2017 - April 7 at 8:21 PM logoShort Interest in ADMA Biologics Inc (ADMA) Rises By 13.6% - April 6 at 11:51 AM logoBiotest AG: Discussions regarding possible business combination - March 29 at 8:27 PM logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA - PR Newswire (press release) - March 28 at 8:02 AM logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA - March 28 at 8:02 AM logoADMA BIOLOGICS, INC. Financials - March 2 at 3:30 PM logoADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi - February 24 at 6:19 PM logoADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones - February 24 at 6:19 PM logoADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers - February 18 at 7:49 AM logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - - February 17 at 9:41 AM logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - - February 17 at 9:41 AM logoBlood Plasma Market 2017-2021 Key Regions Competitive Analysis - January 27 at 9:45 PM logoADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals - January 25 at 1:43 AM logoDGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - - January 24 at 1:25 AM logoADMA Biologics upgraded by Maxim Group - January 23 at 8:24 PM logoADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu - January 23 at 8:24 PM



ADMA Biologics (ADMA) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff